Scleroderma & IL6

International Journal of Rheumatology is a peer-reviewed, open access journal that publishes…|By Hindawi Publishing Corporation

Scleroderma is possibly the most challenging autoimmune disease to treat, mainly because we still lack effective treatment tools for its fibrosing complications: especially in the skin and the lungs. Targeting IL6 looks promising.

Interleukin-6: a new therapeutic target in systemic sclerosis?

Clinical & Translational Immunology homepage

Actemra Looks Promising in Scleroderma

Benefits with tocilizumab seen in skin scores and lung function. is a leading portal for the pharmaceutical industry, providing industry…

Desperate situations call for desperate measures.